Advertisement

Hetero Healthcare Starts Supply of 60,000 Vials for Remdesivir to India, Maha to Get Highest Vials

Follow The Hawk on Google News+ Follow

Advertisement

Hetero Healthcare Ltd is supplying 60,000 vials of Covifor, generic version of Remdesivir injection in the country from July 13 to 20, the company website said.

Covifor is the first generic brand of Remdesivir, which is meant for treatment of COVID-19 patients that are adults and children, hospitalised with severe symptoms of the disease.

Advertisement

The drug is available in 100 mg vial (Injectable). It needs to be administered intravenously in a hospital, critical care setting, under the supervision of a registered medical practitioner.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

Out of 60,000 vials, Maharashtra, which has the highest number of COVID-19 cases in the country will get 12,500 followed by Delhi and Telangana with 10,000 and 9,000 respectively.

According to the website, Tamil Nadu, Gujarat, Andhra Pradesh and Karnataka will get 7500, 6000, 2000 and 3000 respectively while the rest of the country will get 10,000 injections.

Advertisement

The company has supplied the drug to as many as 166 hospitals in Maharashtra and 53 in the national capital. When it comes to Telangana , Hetero supplied 14,502 vials, the information available at 11 AM on the site on Wednesday said.

Also read'Fatty liver-free campaign' in Ranchi from Nov 23, MoS Sanjay Seth to take lead

Remdesivir is the only drug approved by the United States Food and Drug Administration (USFDA) for Emergency Use Authorisation (EUA) treatment of adult and paediatric patients hospitalised with suspected or laboratory confirmed COVID-19 infection.

Meanwhile, Dr Reddy's Laboratories Ltd, which also has a non-exclusive licensing agreement with Gilead Sciences Inc to register, manufacture and sell the investigational drug, Remdesivir in 127 countries including India is yet to get a nod from the DCGI to start making the drug in the country, sources said.

—PTI

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST